GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibikase Therapeutics Inc (NAS:IKT) » Definitions » Land And Improvements

IKT (Inhibikase Therapeutics) Land And Improvements : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inhibikase Therapeutics Land And Improvements?

Inhibikase Therapeutics's land and improvements for the quarter that ended in Sep. 2024 was $0.00 Mil.

Inhibikase Therapeutics Land And Improvements Historical Data

The historical data trend for Inhibikase Therapeutics's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibikase Therapeutics Land And Improvements Chart

Inhibikase Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Land And Improvements
Get a 7-Day Free Trial - - - - -

Inhibikase Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Inhibikase Therapeutics Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Inhibikase Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibikase Therapeutics Inc (NAS:IKT) » Definitions » Land And Improvements
Comparable Companies
HOTH TENX ZIVO ABVC ZVSA SILO ENDV TCON XBIO KPRX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA, USA, 30339
Website
https://www.inhibikase.com
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Executives
Paul C Grint director 7757 DOUGHILL COURT, SAN DIEGO CA 92127
Dennis N Berman director 9605 SCRANTON RD, STE 240, SAN DIEGO CA 92121
Roy Lester Freeman director 256 SUMMIT AVE, BROOKLINE MA 02446
Gisele Dion director C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Milton H. Werner director, 10 percent owner, officer: President and CEO 3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339
Joseph Frattaroli officer: Cheif Financial Officer
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Daniel Kalman 10 percent owner 3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339